These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 7924209)

  • 21. In vitro activity of FK-037, a novel parenteral cephalosporin, against bacterial isolates from neutropenic cancer patients.
    Dholakia N; Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T; Bodey GP
    Eur J Clin Microbiol Infect Dis; 1994 Aug; 13(8):679-85. PubMed ID: 7813504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group.
    Biedenbach DJ; Johnson DM; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):299-305. PubMed ID: 10668589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro evaluation of cefepime and other broad-spectrum beta-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group.
    Lewis MT; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):285-90. PubMed ID: 10668587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro evaluation of broad-spectrum beta-lactams in the philippines medical centers: role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group.
    Johnson DM; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):291-7. PubMed ID: 10668588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro evaluation of cefepime and other broad-spectrum beta-lactams for isolates in Malaysia and Singapore medical centers. The Malaysia/Singapore Antimicrobial Resistance Study Group.
    Biedenbach DJ; Lewis MT; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):277-83. PubMed ID: 10668586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative in vitro activity of FK-037, a new cephalosporin antibiotic.
    Clarke AM; Zemcov SJ; Hubinette MM
    Diagn Microbiol Infect Dis; 1994 Sep; 20(1):27-32. PubMed ID: 7867295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Pfaller MA; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):63-8. PubMed ID: 16650951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula.
    Johnson CC; Livornese L; Gold MJ; Pitsakis PG; Taylor S; Levison ME
    J Antimicrob Chemother; 1995 Jun; 35(6):765-73. PubMed ID: 7559188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolates.
    Washington JA; Jones RN; Allen SD; Gerlach EH; Koontz FP; Murray PR; Pfaller MA; Erwin ME
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1508-11. PubMed ID: 1929319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro evaluation of broad-spectrum beta-lactams tested in medical centers in Korea: role of fourth-generation cephalosporins. The Korean Antimicrobial Resistance Study Group.
    Lewis MT; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):317-23. PubMed ID: 10668591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the in vitro activity of cefepime compared to other broad-spectrum cephalosporins against clinical isolates from eighteen Brazilian hospitals by using the Etest.
    Sader HS; Mimiça I; Rossi F; Zoccoli C; Montelli AC; Sampaio JL; Segura AJ; Magalhães M; Nowakonski A; Mendes CM
    Diagn Microbiol Infect Dis; 1997 Jun; 28(2):87-92. PubMed ID: 9239500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in vitro activity of cefepime against nosocomial isolates.
    Sofianou D; Tsoulfa S; Kontodimou L; Polydorou F; Malaka E
    J Chemother; 1997 Oct; 9(5):341-6. PubMed ID: 9373789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro antibacterial activities of FK037: a new parenteral cephalosporin.
    Inoue K; Inoue E; Mitsuhashi S
    Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro activity of the two new oral cephalosporin metabolites RO 19-5247 and RO 15-8074.
    Aldridge KE; Schiro DD; Sanders CV
    Eur J Clin Microbiol; 1987 Oct; 6(5):564-9. PubMed ID: 3436316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of Ro 09-1428 compared to other cephalosporins.
    Chin NX; Gu JW; Fang W; Neu HC
    Eur J Clin Microbiol Infect Dis; 1991 Aug; 10(8):669-75. PubMed ID: 1748124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group.
    Lewis MT; Yamaguchi K; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):307-15. PubMed ID: 10668590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.
    Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME
    Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines.
    Gerlach EH; Jones RN; Allen SD; Koontz FP; Murray PR; Pfaller MA; Washington JA; Erwin ME
    Diagn Microbiol Infect Dis; 1992 Aug; 15(6):537-43. PubMed ID: 1424507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.